Impact of managed care on the use of biologic agents for rheumatoid arthritis
- 15 June 2005
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 53 (3) , 423-430
- https://doi.org/10.1002/art.21178
Abstract
To compare the use of biologic agents among persons with rheumatoid arthritis (RA) in managed care and fee-for-service settings. The present study uses data from the University of California, San Francisco RA Panel Study in which 529 patients with RA from a random sample of northern California rheumatologists were interviewed annually between 1999 and 2002 using a structured survey instrument. Linear and logistic regression were used to compare current utilization, initiation, and cessation of biologic agents and other treatments among patients with RA in managed care and fee-for-service settings, with and without adjustment for differences in demographic and health characteristics. After adjustment, patients with RA in health maintenance organizations (HMOs) were significantly less likely to use biologic agents than those in other managed care settings (difference of -6.6%; 95% confidence interval [95% CI] -11.4%, -1.7%) or than those in fee-for-service settings (difference of -12.5%; 95% CI -19.0%, -5.9%); patients in other managed care settings and fee-for-service did not differ significantly in their use of biologic agents. Patients with RA in HMOs were significantly less likely than those in other managed care settings to initiate the use of biologic agents (difference of -7.3%; 95% CI -11.5%, -3.1%); there were no other differences between patients in HMOs and those in other managed care and fee-for-service settings in rates of initiation or cessation of these agents. Patients with RA in HMOs were less likely to use methotrexate, cyclooxygenase 2 (COX-2) inhibitors, and corticosteroids than those in other managed care settings; they were also less likely to use COX-2 inhibitors than those in fee-for-service settings. Patients with RA in HMOs were significantly less likely to use biologic agents than those in other managed care and fee-for-service settings, primarily due to lower rates of initiation.Keywords
This publication has 22 references indexed in Scilit:
- Health Benefits In 2003: Premiums Reach Thirteen-Year High As Employers Adopt New Forms Of Cost SharingHealth Affairs, 2003
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- On The ‘Efficiency’ Of Managed Care PlansHealth Affairs, 2000
- The New Dominance Of Managed Care: Insurance Trends In The 1990sHealth Affairs, 1997
- Managed care and arthritis care: Patients and providers under the new medical care organizationsArthritis & Rheumatism, 1995
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Razing a Tower of Babel: A Taxonomy for Managed Care and Health Insurance PlansJournal of Health Politics, Policy and Law, 1993
- Health Outcomes for a Chronic Disease in Prepaid Group Practice and Fee for Service SettingsMedical Care, 1986
- A Comparison of the Treatment of Rheumatoid Arthritis in Health Maintenance Organizations and Fee-for-Service PracticesNew England Journal of Medicine, 1985
- Chronic Disease and Health System PerformanceMedical Care, 1985